Download the Free Unbound MEDLINE PubMed App to your smartphone or tablet.
Available for iPhone, iPad, iPod touch, and Android.
J Gastrointest Oncol [journal]
- Primary hepatic anaplastic large cell ki-1 lymphoma and celiac disease: a casual association? [Journal Article]
- J Gastrointest Oncol 2013 Mar; 4(1):109-13.
- Adenocarcinoma of the proximal rectum and synchronous non-Hodgkin's lymphoma. [Journal Article]
- J Gastrointest Oncol 2013 Mar; 4(1):101-2.
- A molecularly confirmed neuroendocrine tumor resulting from Lynch Syndrome. [Journal Article]
- J Gastrointest Oncol 2013 Mar; 4(1):95-6.
- The role of EGFR monoclonal antibodies (MoABs) cetuximab/panitumab, and BRAF inhibitors in BRAF mutated colorectal cancer. [Journal Article]
- J Gastrointest Oncol 2013 Mar; 4(1):72-81.
- Fine needle aspiration biopsy of malignant mass lesions in the liver: a revisit of diagnostic profiles and challenges. [Journal Article]
- J Gastrointest Oncol 2013 Mar; 4(1):5-7.
- The role of local excision in invasive adenocarcinoma of the ampulla of Vater. [Journal Article]
- J Gastrointest Oncol 2013 Mar; 4(1):1-2.
- Adenocarcinoma associated with tail gut cyst. [Journal Article]
- J Gastrointest Oncol 2013 Mar; 4(1):97-100.
Primary adenocarcinomas of the presacral (retrorectal) space are rare. The diagnosis is usually delayed because of non-specific symptoms, and is made after a biopsy or surgery. These carcinomas arise from cystic lesions developing from remnants of the embryological postanal gut containing mucous-secreting epithelium, known as tail gut cysts. The potential for infection, perianal fistulas and most importantly, malignant change warrants an early complete surgical resection. From an oncologist's perspective, the management of these carcinomas has varied, and has included adjuvant chemotherapy and/or radiation therapy. We describe here a rare case of adenocarcinoma associated with a tail gut cyst that was discovered incidentally and resected by a posterior approach (Kraske procedure). The patient has had clinical and periodic radiologic surveillance without any evidence of cancer recurrence for over a year and a half.
- Socioeconomic status, p53 abnormalities, and colorectal cancer. [Journal Article]
- J Gastrointest Oncol 2013 Mar; 4(1):40-4.
Low socioeconomic status (SES) has been associated with abnormal expression of p53 in breast cancer, but this relationship has not been evaluated for colorectal cancer (CRC). A cohort of CRC patients was evaluated to determine if SES is associated with abnormal p53 expression.The study population consisted of 249 patients who underwent curative or palliative resections for CRCs at the University of Alabama at Birmingham Hospital. Measures of SES and potential confounders were abstracted from medical records. Abnormal nuclear accumulation of p53 (p53) was measured in CRCs by immunohistochemistry. Logistic regression was used to assess the relationship between low SES and p53.Over half (56.2%) of the patients exhibited p53 in their CRCs. After adjustment, the odds ratio for p53 was 1.28 (95% CI =0.55, 2.99) for Medicaid patients relative to those without Medicaid coverage. There was no association between the prevalence of p53 and unemployment, private insurance coverage, or having Medicare due to disability.The odds of having p53 were 1.28 times higher for patients with Medicaid coverage, although these findings were not statistically significant. The results of this pilot study, however, provide evidence of a molecular basis for the decreased survival of low SES patients with CRC.
- Soft tissue tumors of the anorectum: rare, complex and misunderstood. [Journal Article]
- J Gastrointest Oncol 2013 Mar; 4(1):82-94.
Anorectal soft tissue tumors are uncommon and often present both diagnostic and therapeutic challenges. Although many of these tumors are identified with imaging performed for unrelated reasons, most present with nonspecific symptoms that can lead to a delay in diagnosis. Historically, radical surgery (abdominoperineal resection) has been the mainstay of treatment for both benign and malignant anorectal soft tissue tumors. However, a lack of proven benefit in benign disease along with changes in technology has called this practice into question. In addition, the role of radiation and/or chemotherapy remains controversial. In this manuscript, we review the history and current status of anorectal soft tissue tumor management, with a particular focus on challenges in optimizing survival.